Ontology highlight
ABSTRACT:
SUBMITTER: Van Allen EM
PROVIDER: S-EPMC3947264 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Van Allen Eliezer M EM Wagle Nikhil N Sucker Antje A Treacy Daniel J DJ Johannessen Cory M CM Goetz Eva M EM Place Chelsea S CS Taylor-Weiner Amaro A Whittaker Steven S Kryukov Gregory V GV Hodis Eran E Rosenberg Mara M McKenna Aaron A Cibulskis Kristian K Farlow Deborah D Zimmer Lisa L Hillen Uwe U Gutzmer Ralf R Goldinger Simone M SM Ugurel Selma S Gogas Helen J HJ Egberts Friederike F Berking Carola C Trefzer Uwe U Loquai Carmen C Weide Benjamin B Hassel Jessica C JC Gabriel Stacey B SB Carter Scott L SL Getz Gad G Garraway Levi A LA Schadendorf Dirk D
Cancer discovery 20131121 1
Most patients with BRAF(V600)-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely understood. We performed whole-exome sequencing on formalin-fixed, paraffin-embedded tumors from 45 patients with BRAF(V600)-mutant metastatic melanoma who received vemurafenib or dabrafenib monotherapy. Genetic alterations in known or putative RAF inhibitor resista ...[more]